Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T47077
(Former ID: TTDI01591)
|
|||||
| Target Name |
Prostaglandin receptor (PTGR)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Alopecia [ICD-11: ED70] | |||||
| 2 | Glaucoma [ICD-11: 9C61] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Bimatoprost | Drug Info | Approved | Alopecia | [2], [3] | |
| 2 | Unoprostone | Drug Info | Approved | Glaucoma/ocular hypertension | [4] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | Iclaprim | Drug Info | Phase 3 | Bacterial infection | [5] | |
| Discontinued Drug(s) | [+] 5 Discontinued Drugs | + | ||||
| 1 | Taprostene | Drug Info | Discontinued in Phase 3 | Thrombosis | [7], [8] | |
| 2 | TEI-6122 | Drug Info | Discontinued in Phase 2 | Diabetic complication | [9] | |
| 3 | ZD-4953 | Drug Info | Discontinued in Phase 2 | Pain | [10] | |
| 4 | YP-008 | Drug Info | Terminated | Psoriasis vulgaris | [11] | |
| 5 | YP-009 | Drug Info | Terminated | Solid tumour/cancer | [12] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 7 Modulator drugs | + | ||||
| 1 | Bimatoprost | Drug Info | [13] | |||
| 2 | Unoprostone | Drug Info | [1], [4] | |||
| 3 | Iclaprim | Drug Info | [14] | |||
| 4 | Taprostene | Drug Info | [15] | |||
| 5 | TEI-6122 | Drug Info | [16] | |||
| 6 | ZD-4953 | Drug Info | [17] | |||
| 7 | IP-1200 | Drug Info | [20] | |||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | YP-008 | Drug Info | [18] | |||
| Agonist | [+] 1 Agonist drugs | + | ||||
| 1 | YP-009 | Drug Info | [19] | |||
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1958). | |||||
| REF 3 | ClinicalTrials.gov (NCT01387906) Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo. U.S. National Institutes of Health. | |||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 5 | How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025167) | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1968). | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000164) | |||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003140) | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006843) | |||||
| REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026448) | |||||
| REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026449) | |||||
| REF 13 | Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95. | |||||
| REF 14 | Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. | |||||
| REF 15 | Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807. | |||||
| REF 16 | The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302. | |||||
| REF 17 | WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease. | |||||
| REF 18 | CA patent application no. 841416, Method of selecting therapeutic indications. | |||||
| REF 19 | YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007 | |||||
| REF 20 | Clinical pipeline report, company report or official report of Immunologic. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.